Abnormal activation of GSK-3β has been associated with several neurological and psychiatric disorders that share developmental abnormalities and altered neurocircuitry maintenance, such as schizophrenia, bipolar disorder, autism, and Alzheimer’s disease (AD) [48,49,50]. Here, GSK3B is linked to early-onset autosomal dominant Alzheimer disease.